Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.

While the activation of the proto-oncogenes has been implicated in the development and progression of cancer of many tissues, the role of oncogenes in the development of oesophageal adenocarcinoma has not been defined. Fifteen patients who had undergone resection for oesophageal adenocarcinoma and 15 who had undergone oesophagectomy or biopsy for Barrett's oesophagus were studied. The latter patients also had adjacent normal gastric mucosa biopsied for comparison with the metaplastic oesophageal mucosa. The mucosal samples were snap frozen and subsequently stained with monoclonal antibodies to the following oncogene associated proteins; c-erbB2 (neu and CE-1) (external domain), c-erbB2 (NCL-CB11) (internal domain), c-src, c-ras, c-myc, c-fos, c-jun, and the onco-suppressor gene--p53. All tumours were well or moderately differentiated adenocarcinomas arising from the lower third of the oesophagus. Eleven specimens showed strong membraneous staining with both c-erbB2 (neu) and c-erbB2 (CBL-CB11). Seven specimens showed strong nuclear staining with p53 onco-suppressor gene. Three specimens were positive for c-ras and c-src, and two were positive for c-jun. In Barrett's epithelium, nine specimens were positive for c-erbB2 (neu and CB11), three were positive for c-src, two were positive for c-ras and c-jun, and one was positive for c-fos. Two of the gastric mucosal biopsy specimens expressed c-erbB2 weakly but no other oncogenes were found. The frequency of positive staining for c-erbB2 is very high, compared with the expression of these genes in other tumours. It is also concluded that errors in the onco-suppressor gene p53, and especially in the external and internal domains of c-erbB2, which is also often expressed in Barrett's mucosa, may be implicated in the development of adenocarcinoma of the oesophagus.

[1]  D. Hopwood,et al.  Abnormal expression of growth regulatory factors in Barrett's oesophagus. , 1991, Clinical science.

[2]  J. Bartek,et al.  Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. , 1991, Oncogene.

[3]  W. Gullick,et al.  c‐erbB‐2 proto‐oncogene expression and its relationship to survival in gastric carcinoma: An immunohistochemical study on archival material , 1991, International journal of cancer.

[4]  Takuma Sasaki,et al.  Expression of C‐erbB‐2 oncoprotein in gastric carcinoma. Immunoreactivity for C‐erbB‐2 protein is an independent indicator of poor short‐term prognosis in patients with gastric carcinoma , 1991, Cancer.

[5]  R. Baserga,et al.  Growth regulation of the PCNA gene. , 1991, Journal of cell science.

[6]  S. Shousha,et al.  c-erbB-2 expression in different histological types of invasive breast carcinoma. , 1991, Journal of clinical pathology.

[7]  E. Appella,et al.  Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Kung,et al.  Native avian c-erbB gene expresses a secreted protein product corresponding to the ligand-binding domain of the receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R Montesano,et al.  Frequent mutation of the p53 gene in human esophageal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[10]  W. Gullick,et al.  c‐erbB‐2 oncogene expression in ovarian cancer , 1990, The Journal of pathology.

[11]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[13]  P. D. Boyrer In reply: the overhead question. , 1990, Science.

[14]  K. Sikora The Molecules of Cancer , 1990, Journal of the Royal College of Physicians of London.

[15]  N. Lemoine,et al.  The c‐erbB‐2 proto‐oncogene in human pancreatic cancer , 1990, The Journal of pathology.

[16]  Kazuhiro Yoshida,et al.  pp60c‐src protein kinase activity in human gastric carcinomas , 1990, International journal of cancer.

[17]  K. Sikora Cancer genes in gastrointestinal malignancy. , 1990, Bailliere's clinical gastroenterology.

[18]  M. Weber,et al.  Inhibition of epidermal growth factor receptor biosynthesis caused by the src oncogene product, pp60v-src , 1990, Molecular and cellular biology.

[19]  S. Meltzer,et al.  Tissue-specific expression of c-Ha-ras in premalignant gastrointestinal mucosae. , 1989, Experimental and molecular pathology.

[20]  T. Ravikumar,et al.  Ras gene activation and epidermal growth factor receptor expression in human colon cancer. , 1989, The Journal of surgical research.

[21]  D. Spandidos,et al.  Expression of the ras oncoprotein in gastric carcinomas and adjacent mucosa. , 1989, Anticancer research.

[22]  W. Gullick,et al.  c‐erbB‐2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study , 1989, The Journal of pathology.

[23]  N. Benvenisty A Molecular View of Tissue Differentiation and Development , 1989, Journal of the Royal College of Physicians of London.

[24]  J. Varley,et al.  An immunohistochemical and in situ hybridization study of c‐myc and c‐erbB‐2 expression in primary human breast carcinomas , 1989, The Journal of pathology.

[25]  A. Tigges,et al.  Expression of the nuclear oncogene p53 in colon tumours , 1989, The Journal of pathology.

[26]  D. Spandidos,et al.  Oncogenes and onco‐suppressor genes: Their involvement in cancer , 1989, The Journal of pathology.

[27]  D. Nathans,et al.  Induction of protooncogene c-jun by serum growth factors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Walker,et al.  p21 ras protein expression in benign and malignant , 1988, The Journal of pathology.

[29]  M. Lavin,et al.  Immunocytochemical demonstration of p21ras in normal and transitional cell carcinoma urothelium , 1988, The Journal of pathology.

[30]  M. Yaniv,et al.  Transcriptional activation of c-jun during the G0/G1 transition in mouse fibroblasts , 1988, Nature.

[31]  N. Nomura,et al.  Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. , 1988, Oncogene.

[32]  A. Ochiai,et al.  Immunohistochemical detection of c-myc oncogene product in human gastric carcinomas: expression in tumor cells and stromal cells. , 1987, Japanese journal of cancer research : Gann.

[33]  D. Ransohoff,et al.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.

[34]  D. F. Petersen,et al.  Cell growth and division. II. Experimental studies of cell volume distributions in mammalian suspension cultures. , 1967, Biophysical journal.

[35]  L. Bonelli Adenocarcinoma in Barrett's oesophagus. I: , 1993 .

[36]  D. Hopwood,et al.  Expression of epidermal growth factor, transforming growth factor alpha and their receptor in gastro-oesophageal diseases. , 1993, Digestive diseases.

[37]  W. Gullick,et al.  Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. , 1991, British medical bulletin.

[38]  N. Kamada,et al.  Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. , 1991, Cancer research.

[39]  D. Lane,et al.  p53: oncogene or anti-oncogene? , 1990, Genes & development.

[40]  T. Graf,et al.  Relationships Between Oncogenes and Growth Control , 1990 .

[41]  R. D. Cohen The metabolic and molecular basis of acquired disease , 1990 .

[42]  S. N. Fedorov,et al.  [Proto-oncogene expression in human carcinomas of the stomach and in the gastric mucosa of rats exposed to N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis]. , 1989, Eksperimental'naia onkologiia.

[43]  Fedorov Sn,et al.  [Proto-oncogene expression in human carcinomas of the stomach and in the gastric mucosa of rats exposed to N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric carcinogenesis]. , 1989 .

[44]  H. Ikeda,et al.  Analysis of ras gene expression in stomach cancer by anti-ras p21 monoclonal antibodies. , 1988, Cancer detection and prevention.

[45]  D. Wheatley,et al.  Cell growth and division , 1982 .

[46]  M. Hollstein,et al.  Frequent mutation of the p 53 gene in human esophageal cancer ( tumor suppressor gene / DNA sequence analysis / nitrosamines ) , 2022 .